Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
stocks
The 10 best US dividend shares
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,013.60 | 8.30 | -0.10% |
| CAC 40 | 7,285.86 | 44.11 | -0.60% |
| DAX 40 | 21,205.86 | 105.16 | -0.49% |
| Dow JONES (US) | 38,170.41 | 971.82 | -2.48% |
| FTSE 100 | 8,275.66 | 0.06 | 0.00% |
| HKSE | 21,387.39 | 7.75 | -0.04% |
| NASDAQ | 15,870.90 | 415.55 | -2.55% |
| Nikkei 225 | 34,191.28 | 88.64 | -0.26% |
| NZX 50 Index | 11,956.40 | 162.59 | -1.34% |
| S&P 500 | 5,158.20 | 124.50 | -2.36% |
| S&P/ASX 200 | 7,816.30 | 2.80 | -0.04% |
| SSE Composite Index | 3,301.59 | 10.16 | 0.31% |